Anixa Biosciences (ANIX)
(Delayed Data from NSDQ)
$3.44 USD
-0.18 (-4.97%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $3.39 -0.05 (-1.45%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.44 USD
-0.18 (-4.97%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $3.39 -0.05 (-1.45%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Zacks News
Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated
by Zacks Equity Research
Amicus (FOLD) rises 13% as it reports second-quarter 2024 results, wherein both earnings and sales beat the Zacks Consensus Estimate. The company updates its financial guidance for 2024.
Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Cytokinetics (CYTK) reports wider-than-expected Q2 loss as operating expenses increase. CYTK is on track to complete the rolling NDA submission for aficamten in the third quarter.
Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised
by Zacks Equity Research
Gilead (GILD) Q2 earnings and sales beat estimates on high HIV, oncology and liver disease drug sales and low expenses.
Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kymera (KYMR) reports a narrower-than-expected loss in the second quarter. The company expects the current cash balance to provide a runway into the first half of 2027.
Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intra-Cellular (ITCI) reports second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
Viatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss
by Zacks Equity Research
Viatris' (VTRS) earnings beat estimates in the second quarter but sales miss the same. New products are performing well and the rise in annual guidance for these products' sales is encouraging.
Catalyst (CPRX) Rises as Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Catalyst (CPRX) gains as it reports strong second-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, primarily driven by strong Firdapse sales.
Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel Revenues
by Zacks Equity Research
Exelixis (EXEL) beats on earnings and sales in the second quarter. Its shares are trading up in response to the results.
Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues
by Zacks Equity Research
Acadia (ACAD) reports encouraging second-quarter results as both earnings and revenues beat estimates, driven by higher Nuplazid and Daybue sales.
Novo Nordisk (NVO) Falls as Q2 Earnings and Sales Miss, View Up
by Zacks Equity Research
Novo Nordisk (NVO) falls as it reports lower-than-expected Q2 results, missing both earnings and revenue estimates. However, sales of Diabetes and Obesity care products increase year over year.
Zoetis (ZTS) Q2 Earnings & Revenues Beat, '24 Outlook Raised
by Zacks Equity Research
Zoetis (ZTS) reports better-than-expected Q2 results, beating both earnings and revenue estimates, primarily driven by strong sales of companion animal products. Management raises the 2024 outlook.
Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Axsome's (AXSM) bottom line declines year over year in the second quarter. Strong sales of Auvelity drive revenues.
Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up
by Zacks Equity Research
Ultragenyx (RARE) reports encouraging second-quarter 2024 results, beating both earnings and revenue estimates driven by the year-over-year increase of Crysvita and Dojolvi sales.
Apellis (APLS) Q2 Earnings Beat, Syfovre Sales Drive Revenues
by Zacks Equity Research
Apellis (APLS) reports better-than-expected second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.
Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug
by Zacks Equity Research
Dermata (DRMA) announces reaching an agreement with the FDA to begin a late-stage pivotal clinical program for its acne treatment candidate, DMT310. The stock rises 7%.
Ardelyx (ARDX) Up on Xphozah's Orphan Tag for Hyperphosphatemia
by Zacks Equity Research
Ardelyx (ARDX) announces that the FDA has granted orphan drug designation to Xphozah for the treatment of pediatric hyperphosphatemia. The stock rises 4%.
Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates
by Zacks Equity Research
Kodiak (KOD) reports better-than-expected third-quarter 2023 results and provides updates regarding its pipeline development plans.
Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies
by Zacks Equity Research
Moleculin (MBRX) announces positive interim data from its early-mid-stage studies of Annamycin in blood and lung cancer indications, along with encouraging third-quarter results. The stock rises 7%.
Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) reports better-than-expected fiscal second-quarter 2023 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.
Intellia (NTLA) Beats on Q3 Earnings, Provides Pipeline Update
by Zacks Equity Research
Intellia (NTLA) reports mixed third-quarter 2023 results. Management provides developmental and regulatory updates on its key pipeline candidates.
FATE Q3 Earnings Beat on Lower Expenses, Revenues Fall Y/Y
by Zacks Equity Research
FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating expenses. The stock rises about 5% in the after-market hours.
Catalyst (CPRX) Q3 Earnings Miss, Sales Top, '23 View Up
by Zacks Equity Research
Catalyst (CPRX) reports mixed third-quarter results. Firdapse and Fycompa sales continue to boost revenues. Management raises 2023 financial guidance. The stock gains 6% in the after-market hours.
Vertex (VRTX) Q3 Earnings Beat, Sales Miss, Raises '23 View
by Zacks Equity Research
Vertex's (VRTX) third-quarter results reflect a year-over-year increase in revenues. The company raises its net product sales guidance for 2023.
Deciphera (DCPH) Stock Gains 17% on Q3 Earnings & Sales Beat
by Zacks Equity Research
Deciphera (DCPH) reports better-than-expected third-quarter 2023 results, wherein earnings and revenues beat estimates, driven by increased Qinlock sales. The stock rises 17%.
Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) reports better-than-expected fiscal second-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.